Champions Oncology (CSBR) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to 1.23%.
- Champions Oncology's EBIT Margin fell 42000.0% to 1.23% in Q4 2025 from the same period last year, while for Oct 2025 it was 3.68%, marking a year-over-year increase of 51500.0%. This contributed to the annual value of 8.0% for FY2025, which is 226600.0% up from last year.
- According to the latest figures from Q4 2025, Champions Oncology's EBIT Margin is 1.23%, which was down 42000.0% from 3.77% recorded in Q3 2025.
- In the past 5 years, Champions Oncology's EBIT Margin ranged from a high of 26.4% in Q1 2025 and a low of 21.44% during Q1 2024
- Moreover, its 5-year median value for EBIT Margin was 2.0% (2022), whereas its average is 3.56%.
- In the last 5 years, Champions Oncology's EBIT Margin crashed by -255300bps in 2023 and then skyrocketed by 478500bps in 2025.
- Over the past 5 years, Champions Oncology's EBIT Margin (Quarter) stood at 2.23% in 2021, then crashed by -98bps to 0.05% in 2022, then plummeted by -34564bps to 16.89% in 2023, then soared by 132bps to 5.43% in 2024, then crashed by -77bps to 1.23% in 2025.
- Its EBIT Margin was 1.23% in Q4 2025, compared to 3.77% in Q3 2025 and 16.24% in Q2 2025.